The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Open accessAbstract
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of chemotherapy led to a dramatic improvement in prognosis for patients with localized osteosarcoma; long-term survival rates of less than 20% improved to 65% to 70% after the advent of multiagent chemotherapy regimens. Controversy concerning the ideal combination of chemotherapy agents ensued throughout the last quarter of the 20th century because of conflicting and often nonrandomized data. However, large cooperative group studies and international collaboration have demonstrated that the most effective regimens include the combination of high-dose methotrexate, doxorubicin, and cisplatin (MAP). The introduction of biologic agents such as muramyl tripeptide and the use of additional cytotoxic chemotherapy such as ifosfamide have not definitively improved the survival of patients with osteosarcoma. Collaborative efforts to increase understanding of the biology of osteosarcoma and the use of preclinical models to test novel agents will be critical to identify the path toward improving outcomes for patients. Once promising agents are identified, an international infrastructure exists for clinical trials. Herein, biologic, preclinical, and clinical trial efforts will be described along with future international collaborative strategies to improve outcomes for patients who develop this challenging tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · cited 2×
“most commonly occurs in the distal femur (43%), proximal tibia (23%), or humerus (10%).(1) The typ-”
BackgroundSelf-citationCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D., Bernstein, M. L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6<2163::aid-cncr2820430602>3.0.co;2-s · Cited by 592
Provisor, A. J., Ettinger, L. J., Nachman, J. B., Krailo, M. D., Makley, J. T., Yunis, E. J., Huvos, A. G., Betcher, D. L., Baum, E. S., Kisker, C. T., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.76 · Cited by 461
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Self-citationGoorin, A. M., Schwartzentruber, D. J., Devidas, M., Gebhardt, M. C., Ayala, A. G., Harris, M. B., Helman, L. J., Grier, H. E., & Link, M. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.165 · Cited by 395
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Lewis, I. J., Nooij, M. A., Whelan, J., Sydes, M. R., Grimer, R., Hogendoorn, P. C. W., Memon, M. A., Weeden, S., Uscinska, B. M., van Glabbeke, M., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk015 · Cited by 346
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345
Fuchs, N., Bielack, S. S., Epler, D., Bieling, P., Delling, G., Körholz, D., Graf, N., Heise, U., Jürgens, H., Kotz, R., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008391103132 · Cited by 343
Self-citationWhelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu526 · Cited by 333
Self-citationMiser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317
Bramwell, V. H., Burgers, M., Sneath, R., Souhami, R., van Oosterom, A. T., Voûte, P. A., Rouesse, J., Spooner, D., Craft, A. W., & Somers, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1579 · Cited by 313
Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294
Self-citationStiller, C. A., Bielack, S. S., Jundt, G., & Steliarova-Foucher, E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.015 · Cited by 283
Self-citationLink, M., Goorin, A. M., Horowitz, M. M., et al. (1991) · PubMed · Cited by 259
Chawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., Blay, J.-Y., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 246
Schöffski, P., Ray-Coquard, I. L., Cioffi, A., Bui, N. B., Bauer, S., Hartmann, J. T., Krarup-Hansen, A., Grünwald, V., Sciot, R., Dumez, H., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70230-3 · Cited by 244
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Gorlick, R., Janeway, K., Lessnick, S., Randall, R. L., Marina, N., & on behalf of the COG Bone Tumor Committee (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24429 · Cited by 226
Self-citationBond, M., Bernstein, M. L., Pappo, A., Schultz, K. R., Krailo, M., Blaney, S. M., & Adamson, P. C. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21132 · Cited by 211
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Savage, S. A., Mirabello, L., Wang, Z., Gastier-Foster, J. M., Gorlick, R., Khanna, C., Flanagan, A. M., Tirabosco, R., Andrulis, I. L., Wunder, J. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2645 · Cited by 202
Self-citationPetrilli, A. S., de Camargo, B., Filho, V. O., Bruniera, P., Brunetto, A. L., Jesus-Garcia, R., Camargo, O. P., Pena, W., Péricles, P., Davi, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.5352 · Cited by 188
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Khanna, C., Fan, T. M., Gorlick, R., Helman, L. J., Kleinerman, E. S., Adamson, P. C., Houghton, P. J., Tap, W. D., Welch, D. R., Steeg, P. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2574 · Cited by 178
Self-citationNeoadjuvant chemotherapy for osteosarcoma of the extremity
Bacci, G., Briccoli, A., Ferrari, S., Longhi, A., Mercuri, M., Capanna, R., Donati, D., Lari, S., Forni, C., & DePaolis, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00229-5 · Cited by 174
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
Roth, M., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R., Geller, D., Gill, J., & Gorlick, R. (2014) · Cancer · doi:10.1002/cncr.28461 · Cited by 167
Self-citationLe Deley, M.-C., Guinebretière, J.-M., Gentet, J.-C., Pacquement, H., Pichon, F., Marec-Bérard, P., Entz-Werlé, N., Schmitt, C., Brugières, L., Vanel, D., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.023 · Cited by 162
Gorlick, R., & Khanna, C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.77 · Cited by 157
Self-citationBomgaars, L. R., Bernstein, M. L., Krailo, M., KADOTA, R. P., Das, S., Chen, Z., Adamson, P. C., & Blaney, S. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6103 · Cited by 140
Edmonson, J. H., Green, S., Ivins, J. C., Gilchrist, G. S., Creagan, E. T., Dj, P., Smithson, W. A., Dahlin, D. C., & Taylor, W. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.152 · Cited by 107
International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
Marina, N. M., Bielack, S., Whelan, J. S., Smeland, S., Krailo, M., Sydes, M. R., Butterfaß‐Bahloul, T., Calaminus, G., & Bernstein, M. L. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_18 · Cited by 102
Self-citationTrends and Variability in Survival Among Patients With Osteosarcoma: A 7-Year Update
Taylor, W. F., Ivins, J. C., Pritchard, D. J., Dahlin, D. C., Gilchrist, G. S., & Edmonson, J. H. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60293-6 · Cited by 99
High-dose ifosfamide in advanced osteosarcoma.
Marti, C., Kröner, P. T., Remagen, W., Berchtold, W., Cserhati, M., & Varini, M. (1985) · PubMed · Cited by 89
Kolb, E. A., Gorlick, R. G., Reynolds, C. P., Kang, M. H., Carol, H., Lock, R. B., Keir, S. T., Maris, J. M., Billups, C. A., DesJardins, C., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24517 · Cited by 86
Self-citationHigh-Dose Methotrexate in Osteosarcoma: Let the Questions Surcease—Time for Final Acceptance
Jaffe, N., & Gorlick, R. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7793 · Cited by 74
Self-citationBeristain, A. G., Narala, S., Grappa, M. A. D., & Khokha, R. (2012) · Journal of Cell Science · doi:10.1242/jcs.094029 · Cited by 67
Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors
Zwerdling, T., Krailo, M., Monteleone, P. M., Byrd, R. L., Sato, J. K., Dunaway, R. P., Seibel, N. L., Chen, Z., Strain, J. D., & Reaman, G. H. (2006) · Cancer · doi:10.1002/cncr.21779 · Cited by 62
Beaty, O., Berg, S. L., Blaney, S. M., Malogolowkin, M. H., Krailo, M., Knight, R., Schaiquevich, P. S., Stewart, C. F., Chen, Z., Nelson, M. D., et al. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22544 · Cited by 50
Delaying surgery with chemotherapy for osteosarcoma of the extremities
Bielack, S., Machatschek, J.-N., Flege, S., & Jürgens, H. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.6.1243 · Cited by 48
Self-citationBacci, G., Ferrari, S. M., Tienghi, A., et al. (2001) · European Journal of Surgical Oncology · doi:10.1053/ejso.2000.1056 · Cited by 45
Seibel, N. L., Krailo, M., Chen, Z., Healey, J. H., Breitfeld, P. P., Drachtman, R. A., Greffe, B. S., Nachman, J. B., Nadel, H. R., Sato, J. K., et al. (2007) · Cancer · doi:10.1002/cncr.22553 · Cited by 44
Jacobs, S. S., Fox, E., Krailo, M., Hartley, G., Navid, F., Wexler, L. H., Blaney, S. M., Goodwin, A., Goodspeed, W. J., Balis, F. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1906 · Cited by 44
Kolb, E. A., Gorlick, R. G., Billups, C. A., Hawthorne, T. R., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25099 · Cited by 43
Self-citationLangevin, A., Bernstein, M. L., Kuhn, J. G., Blaney, S. M., Ivy, P. S., Sun, J., Chen, Z., & Adamson, P. C. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21274 · Cited by 27
Chemotherapy for Osteosarcoma without High-Dose Methotrexate: A 12-Year Follow-Up on 53 Patients
Tunn, P., & Reichardt, P. (2007) · Oncology Research and Treatment · doi:10.1159/000100776 · Cited by 23
Phase II study of ifosfamide as a single drug for relapsed paediatric patients
Schwartzman, E., Scopinaro, M. J., & Angueyra, N. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00253230 · Cited by 14
Carrle, D., Dantonello, T. M., & Bielack, S. S. (2007) · Sarcoma · doi:10.1155/2007/76405 · Cited by 12
Self-citationBacci, G., Avella, M., Capanna, R., Boriani, S., Dallari, D., Galletti, S., Giunti, A., Madon, E., Mancini, A., & Mercuri, M. (1988) · PubMed · Cited by 11
Clinical Trials Directive slows registration of paediatric studies
Cannell, E. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70991-3 · Cited by 10
Cited by
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Self-citationSmeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.027 · Cited by 704
Self-citationCurrent and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 689
Self-citationBeird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Self-citationReview of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 395
Metadata
- Authors
- Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-09-20
- Volume
- 33
- Issue
- 27
- Pages
- 3029-3035
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139619092
- Cited by
- 1,567
- References
- 55
- FWCI
- 60.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.